

INTERIM REPORT AS OF SEPTEMBER 30, 2011



## PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS UNDER THEIR OWN NAMES, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

## CONTENTS

- 03 AT A GLANCE / KEY GROUP FIGURES AT A GLANCE
- 04 FOREWORD BY THE BOARD OF MANAGEMENT
- 05 INTERIM GROUP MANAGEMENT REPORT
- 09 CONSOLIDATED BALANCE SHEET  
as of September 30, 2011
- 11 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
for the Period from July 1 to September 30, 2011
- 12 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
for the Period from January 1 to September 30, 2011
- 13 STATEMENT OF CHANGES IN GROUP SHAREHOLDERS' EQUITY  
for the Period from January 1 to September 30, 2011
- 15 CONSOLIDATED CASH FLOW STATEMENT  
for the Period from January 1 to September 30, 2011
- 16 NOTES TO THE GROUP INTERIM REPORT  
for the Period from January 1 to September 30, 2011
- 18 ADDITIONAL INFORMATION

## AT A GLANCE

Sales of € 80.2 million in 9M/2011  
(+15.9%; 9M/2010: € 69.2 million)

Increased EBIT margin of 18.8% in 9M/2011  
(9M/2010: 18.5%)

One-off tax charge of € 1.6 million resulting from  
routine tax audit for FYs 2005 to 2008

Consolidated net income\* of € 11.4 million in 9M/2011  
(+17.4%; 9M/2010: € 9.8 million)

Earnings per share\* of € 0.99 in 9M/2011  
(+16.5%; 9M/2010: € 0.85)

2011 financial guidance reaffirmed  
(sales of € 114 million to € 123 million / EBIT margin > 18.5%)

Development and supply agreement with Quanterix Corp., USA

## KEY GROUP FIGURES AT A GLANCE

in € thousands	01.01. - 09.30.2011	01.01. - 09.30.2010	Change
Sales	80,155	69,149	+ 15.9%
Overall performance	85,871	76,419	+ 12.4%
EBITDA	17,636	14,977	+ 17.8%
EBIT	15,065	12,793	+ 17.8%
Consolidated net income	9,840	9,746	+ 1.0%
Earnings per share (€)	0.85	0.85	+ 0.0%
EBIT margin (%)	18.8%	18.5%	-
Consolidated net income*	11,438	9,746	+ 17.4%
Earnings per share (€)*	0.99	0.85	+ 16.5%

in € thousands	09.30.2011	12.31.2010	Change
Shareholders' equity	77,333	71,879	+ 7.6%
Total assets	112,620	98,836	+ 13.9%
Equity ratio (%)	68.7%	72.7%	-
No. of employees (absolute)	484	440	+ 10.0%

\* adjusted for the one-off item resulting from a routine tax audit for the financial years 2005 to 2008

## FOREWORD BY THE BOARD OF MANAGEMENT

Dear Shareholders,

STRATEC continued to deliver solid growth during the third quarter. By the end of the first nine months of 2011, the Group's sales amounted to € 80.2 million, up 15.9% on the previous year's period. The current year's figures therefore confirm the level of sales growth announced by the company for 2011 as a whole, namely of increasing sales to between € 114 million and € 123 million (corridor). The Group boosted its EBIT by 17.8% to € 15.1 million. Accordingly, the EBIT margin reached 18.8%, exceeding the target of at least 18.5% set for 2011. These business results were driven both by pleasing sales with established systems, as well as by the new systems launched by our customers over the past twelve months.

In mid-August 2011 we concluded a development and supply agreement with the US company Quanterix, under which the two companies will jointly develop and manufacture a fully automated analyzer system to automate Quanterix' technology (single molecule array technology) both in the field of life sciences and for in-vitro diagnostics (IVD). Quanterix expects the market launch of the life sciences system to take place in 2013. The marketing of an IVD platform is scheduled for 2014.

On September 29, 2011, we held our first Analysts' Day at our company headquarters in Birkenfeld. The warm reception granted to this event underlines the great interest in companies with business models offering long-term planning reliability and clear growth strategies.

As part of a nationwide, cross-sector competition, the Munich Strategy Group (MSG) acting together with the daily newspaper "Die Welt" recently identified Germany's most successful medium-sized companies. STRATEC performed excellently in this contest, reaching fifth position from among around 1,600 companies with sales in the category € 15 million to € 350 million. Only those companies that are market leaders in their specific sectors and that have proven track records of superb results over a longer period were singled out in this competition. The ranking is based on two equally weighted criteria, namely sales growth and profitability over the period from 2005 to 2010. Further details can be found on our homepage at [www.stratec.com](http://www.stratec.com) > News.

Birkenfeld, October 2011

The Board of Management of  
STRATEC Biomedical AG



Marcus Wolfinger



Dr. Robert Siegle



Bernd M. Steidle

# INTERIM GROUP MANAGEMENT REPORT

## REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

While sales rose to € 80.2 million in the first nine months of the 2011 financial year, up 15.9% on the previous year's figure (€ 69.1 million), the Group increased its overall performance by 12.4% to € 85.9 million (previous year: € 76.4 million). The cost of materials, by contrast, only rose by 8.9% over the same period from € 37.5 million to € 40.8 million.

Due in particular to the increase in development activities, as well as to the further expansion in production capacities and the acquisition of STRATEC Biomedical USA, Inc. in July of the previous year (increase in personnel expenses from July 1, 2010), personnel expenses rose from € 18.1 million to € 21.2 million. Given this base effect, we do not expect personnel expenses to increase to any significant extent in the coming quarters.

Other operating expenses increased from € 6.5 million to € 7.1 million. Here too, it should be noted that STRATEC Biomedical USA, Inc. has only been included in the consolidated figures since July 1, 2010. Depreciation and amortization rose to € 2.6 million. The outcome of a routine tax audit led to the identification of a one-off additional tax charge of € 1.6 million for previous years (previous year: € 0.0 million), one whose implications will also result in opposing, smaller items in future.

STRATEC thus generated consolidated net income of € 9.8 million in the period under report (previous year: € 9.7 million), corresponding to earnings per share of € 0.85 (previous year: € 0.85).

Excluding the one-off item resulting from the routine tax audit, consolidated net income amounts to € 11.4 million, corresponding to earnings per share of € 0.99.

Due to the launch of serial production on three development projects, inventories rose from € 35.2 million to € 42.8 million. Total receivables and other assets increased from € 22.7 million to € 27.5 million, while cash and cash equivalents rose from € 13.2 million to € 14.2 million in the period under report.

The equity ratio amounts to 68.7%. The increase in non-current financial liabilities to € 9.5 million was due to the taking up of low-interest innovation loans. The rise in accounts payable was driven by higher procurement volumes for raw materials and supplies. Miscellaneous current liabilities and provisions include an amount of around € 10.1 million for prepayments received for development services and an amount of € 1.6 million for a tax charge for previous years.

The inflow of funds from operating activities amounted to € 5.8 million (previous year: € 0.1 million). The STRATEC Group invested € 2.1 million in the first nine months of the 2011 financial year (previous year: € 6.8 million), of which € 2.0 million in property, plant and equipment (previous year: € 6.2 million, especially buildings).

## CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

Three years down the line from the Lehman crisis, in its latest economic outlook the International Monetary Fund (IMF) once again sees the global economy entering a dangerous period. The report expresses alarm at the debt crisis in the euro area and the threat of a global economic downturn. The IMF forecasts that the pace of economic growth will slow in 2011 and 2012, but does not expect to see any recession.

The IMF has cut its forecast for global economic growth, which it now estimates at 4.0% in 2011. That represents a downward revision of 0.3 percentage points compared with its previous forecast. The IMF also expects to see growth of 4.0% in 2012 (previously: 4.5%).

For the euro area, the IMF has forecast economic growth of 1.6% in 2011 and 1.1% in 2012, thus reducing the forecasts issued in June 2011 by 0.4 and 0.6 percentage points respectively.

According to the IMF, Germany will not manage to achieve the level of growth previously hoped for. Growth here is now expected to amount to 2.7% in 2011 (reduction by 0.5 percentage points) and 1.3% in 2012 (reduction by 0.7 percentage points).

The IMF has reduced its forecasts for the USA even more sharply. Accordingly, the US economy is now only expected to grow by 1.5% in 2011 (reduction by 1.0 percentage points) and by 1.8% in 2012 (reduction by 0.9 percentage points).

Global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of medical tests to be performed, but will also result in new, unique opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks, such as the recent recession, only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers and the fact that the work performed is invoiced almost exclusively in euros further minimize the implications of the crisis for STRATEC.

## REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

Based on the latest forecasts and on current information published by our customers, in May 2011 STRATEC released a more specific sales forecast for the 2011 financial year.

Accordingly, STRATEC expects to generate sales in a range of €114 million to €123 million (previously €110 million to €123 million) with an EBIT margin of at least 18.5% in 2011. Medium-term expectations for the period from 2011 to 2013 remain unaffected by current developments. Accordingly, STRATEC continues to expect to achieve average sales growth (CAGR) of at least 17.0% over these three financial years with an EBIT margin of at least 18.5% in 2011, and at least 19.0% in 2012 and 2013. Achievement or any potential exceeding of the upper end of the sales corridor of €123 million in 2011 is dependent on the timing of the planned pending market launches of new systems and their approval in the relevant markets.

All in all, STRATEC can report a positive business performance for the first three quarters of 2011. Given the large number of projects making positive progress, the subdued statements made by various market players in the healthcare and diagnostics industry have so far not been reflected in STRATEC's sales performance. With regard to our customers' purchase planning, there are still no indications that government savings and fiscal policy measures in the euro and dollar regions will have any material implications for our company. STRATEC's business model remains largely independent of macroeconomic factors. Fluctuations in the market, such as volatile test volumes, a development reported in particular in the USA, have so far not been reflected in the talks we have held with customers about new and follow-up projects.



Now that the overall economic situation has recovered following the international economic crisis and the resultant economic downturn, all industrial sectors are nevertheless still confronted with a low level of budgeting reliability, not least on account of the immense debt accumulated by some countries and the resultant potential implications (debt crisis). This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the situation of the company provided on February 22, 2011 upon the compilation of the Annual Report for the 2010 financial year, no new information has arisen which could lead to any change in our assessment of the expected development of the company.

## OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2010 financial year dated February 22, 2011. Reference is made to the "Risk Report" section within the 2010 Group Management Report for details concerning our risk management system and our company's specific opportunity and risk profile.

# CONSOLIDATED BALANCE SHEET

as of September 30, 2011  
of STRATEC Biomedical AG

ASSETS in € thousands	09.30.2011	12.31.2010
<b>NON-CURRENT ASSETS</b>		
Goodwill	4,336	4,480
Other intangible assets	5,676	5,678
Property, plant and equipment	17,083	16,358
Interests in associates	346	342
Deferred tax assets	427	333
	<b>27,868</b>	<b>27,191</b>
<b>CURRENT ASSETS</b>		
Raw materials and supplies	10,660	7,731
Unfinished products, unfinished services	31,201	26,838
Finished products and goods	937	589
Prepayments made	0	3
Trade receivables	18,897	15,817
Future receivables from construction contracts	6,340	5,629
Receivables from associates	115	103
Other receivables and other assets	2,137	1,187
Securities	295	526
Cash and cash equivalents	14,170	13,222
	<b>84,752</b>	<b>71,645</b>
<b>TOTAL ASSETS</b>	<b>112,620</b>	<b>98,836</b>

SHAREHOLDERS' EQUITY AND DEBT in € thousands	09.30.2011	12.31.2010
<b>SHAREHOLDERS' EQUITY</b>		
Share capital	11,672	11,569
Capital reserve	15,139	13,915
Revenue reserves	40,246	32,985
Consolidated net income	9,840	13,039
Other equity	436	371
	<b>77,333</b>	<b>71,879</b>
<b>DEBT</b>		
<b>Non-current debt</b>		
Non-current financial liabilities	9,455	7,420
Pension provisions	321	321
Deferred taxes	1,818	2,055
	<b>11,594</b>	<b>9,796</b>
<b>Current debt</b>		
Current financial liabilities	582	588
Trade payables	5,429	2,842
Liabilities to associates	388	88
Other current liabilities	15,048	10,952
Current provisions	1,788	1,496
Income tax liabilities	458	1,195
	<b>23,693</b>	<b>17,161</b>
<b>TOTAL SHAREHOLDERS' EQUITY AND DEBT</b>	<b>112,620</b>	<b>98,836</b>

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from July 1 to September 30, 2011  
of STRATEC Biomedical AG

in € thousands	07.01.-09.30.2011	07.01.-09.30.2010
<b>Sales</b>	<b>31,764</b>	<b>26,117</b>
Change in volume of finished and unfinished products and unfinished services	-959	1,223
Other own work capitalized	422	365
<b>Overall performance</b>	<b>31,227</b>	<b>27,705</b>
Other operating income	648	242
Cost of raw materials and supplies	14,800	13,201
Cost of purchased services	539	373
Personnel expenses	7,157	6,500
Other operating expenses	2,470	2,270
<b>EBITDA</b>	<b>6,909</b>	<b>5,603</b>
Amortization of intangible assets and depreciation of property, plant and equipment	899	767
<b>EBIT</b>	<b>6,010</b>	<b>4,836</b>
Net financial expenses	-191	-52
<b>Operating result (EBT)</b>	<b>5,819</b>	<b>4,784</b>
Current tax expenses	1,328	1,325
Deferred tax expenses (previous year: tax income)	103	339
Tax charge for previous years *	1,598	0
<b>Consolidated net income</b>	<b>2,790</b>	<b>3,798</b>
<b>Income and expenses recognized directly in equity (after taxes)</b>		
Currency translation of foreign financial statements	419	-98
<b>Comprehensive income</b>	<b>3,209</b>	<b>3,700</b>
<b>Earnings per share in €</b>	<b>0.24</b>	<b>0.33</b>
Number of shares used as basis	11,647,143	11,490,217
<b>Earnings per share, diluted, in €</b>	<b>0.24</b>	<b>0.33</b>
Number of shares used as basis, diluted	11,705,207	11,637,953
<b>Consolidated net income **</b>	<b>4,388</b>	<b>3,798</b>
<b>Earnings per share in € **</b>	<b>0.38</b>	<b>0.33</b>

\* one-off tax charge resulting from a routine tax audit for the financial years 2005 to 2008

\*\* adjusted for the one-off item resulting from a routine tax audit for the financial years 2005 to 2008

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from January 1 to September 30, 2011  
of STRATEC Biomedical AG

in € thousands	01.01.-09.30.2011	01.01.-09.30.2010
<b>Sales</b>	<b>80,155</b>	<b>69,149</b>
Increase in volume of finished and unfinished products and unfinished services	4,554	6,691
Other own work capitalized	1,162	579
<b>Overall performance</b>	<b>85,871</b>	<b>76,419</b>
Other operating income	899	554
Cost of raw materials and supplies	39,470	36,264
Cost of purchased services	1,298	1,189
Personnel expenses	21,230	18,075
Other operating expenses	7,136	6,468
<b>EBITDA</b>	<b>17,636</b>	<b>14,977</b>
Amortization of intangible assets and depreciation of property, plant and equipment	2,571	2,184
<b>EBIT</b>	<b>15,065</b>	<b>12,793</b>
Net financial expenses	-356	-12
<b>Operating result (EBT)</b>	<b>14,709</b>	<b>12,781</b>
Current tax expenses	3,592	3,332
Deferred tax income	321	297
Tax charge for previous years *	1,598	0
<b>Consolidated net income</b>	<b>9,840</b>	<b>9,746</b>
<b>Income and expenses recognized directly in equity (after taxes)</b>		
Currency translation of foreign financial statements	-140	1,030
<b>Comprehensive income</b>	<b>9,700</b>	<b>10,776</b>
<b>Earnings per share in €</b>	<b>0.85</b>	<b>0.85</b>
Number of shares used as basis	11,600,546	11,446,079
<b>Earnings per share, diluted, in €</b>	<b>0.84</b>	<b>0.84</b>
Number of shares used as basis, diluted	11,706,526	11,608,080
<b>Consolidated net income **</b>	<b>11,438</b>	<b>9,746</b>
<b>Earnings per share in € **</b>	<b>0.99</b>	<b>0.85</b>

\* one-off tax charge resulting from a routine tax audit for the financial years 2005 to 2008

\*\* adjusted for the one-off item resulting from a routine tax audit for the financial years 2005 to 2008

# STATEMENT OF CHANGES IN GROUP SHAREHOLDERS' EQUITY

for the Period from January 1 to September 30, 2011  
of STRATEC Biomedical AG

## JANUARY - SEPTEMBER 2010

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Retained earnings	Free revenue reserves
<b>Balance at 12.31.2009</b>	<b>11,446</b>	<b>11,167</b>	<b>18,893</b>	<b>7,540</b>
Dividend payment				
Issue of subscription shares from stock option plans, less costs of capital issue after taxes	37	795		
Allocations due to stock option plans		154		
Allocation to free revenue reserves				3,000
Profit carried forward			3,552	
Disposal of treasury stock		448		
Comprehensive income				
<b>Balance at 09.30.2010</b>	<b>11,483</b>	<b>12,564</b>	<b>22,445</b>	<b>10,540</b>

## JANUARY - SEPTEMBER 2011

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Retained earnings	Free revenue reserves
<b>Balance at 12.31.2010</b>	<b>11,569</b>	<b>13,915</b>	<b>22,445</b>	<b>10,540</b>
Dividend payment				
Issue of subscription shares from stock option plans, less costs of capital issue after taxes	103	1,252		
Allocations due to stock option plans		120		
Issue of treasury stock to employees		-148		
Allocation to free revenue reserves				3,000
Profit carried forward			4,261	
Comprehensive income				
<b>Balance at 09.30.2011</b>	<b>11,672</b>	<b>15,139</b>	<b>26,706</b>	<b>13,540</b>

	Other equity			Group equity
	Consolidated net income	Treasury stock	Currency translation	
	11,674	-998	-435	59,287
	-5,122			-5,122
				832
				154
	-3,000			0
	-3,552			0
		586		1,034
	9,746		1,030	10,776
	<b>9,746</b>	<b>-412</b>	<b>595</b>	<b>66,961</b>

	Other equity			Group equity
	Consolidated net income	Treasury stock	Currency translation	
	13,039	-417	788	71,879
	-5,778			-5,778
				1,355
				120
		205		57
	-3,000			0
	-4,261			0
	9,840		-140	9,700
	<b>9,840</b>	<b>-212</b>	<b>648</b>	<b>77,333</b>

# CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to September 30, 2011  
of STRATEC Biomedical AG

in € thousands	01.01.-09.30.2011	01.01.-09.30.2010
Consolidated net income	9,840	9,746
Depreciation and amortization	2,571	2,184
Current income tax expenses	3,592	3,333
Income taxes paid less income taxes received	-4,132	-3,199
Financial income	-121	-163
Financial expenses	477	175
Interest paid	-246	-174
Interest received	91	63
Other non-cash expenses	556	362
Other non-cash income	-1,162	-99
<b>Cash flow</b>	<b>11,466</b>	<b>12,228</b>
Change in deferred taxes through profit or loss	-321	-297
Profit on disposals of non-current assets	-121	0
Increase in inventories, trade receivables and other assets	-12,490	-15,350
Increase in trade payables and other liabilities	7,275	3,559
<b>Inflow of funds from operating activities</b>	<b>5,809</b>	<b>140</b>
Incoming payments from disposals of non-current assets		
Property, plant and equipment	152	14
Outgoing payments for investments in non-current assets		
Intangible assets	-155	-260
Property, plant and equipment	-1,965	-1,740
Prepayments made / assets under construction	-136	-4,456
Outgoing payment for acquisition of consolidated companies plus overdraft facilities thereby acquired	0	-321
<b>Outflow of funds for investment activities</b>	<b>-2,104</b>	<b>-6,763</b>
Incoming payments from taking up of financial liabilities	2,515	2,500
Outgoing payments for repayment of financial liabilities	-529	-1,301
Incoming payments from issues of shares for employee stock option programs	1,355	833
Dividend payment	-5,778	-5,122
<b>Outflow of funds for financing activities</b>	<b>-2,437</b>	<b>-3,090</b>
<b>Cash-effective change in cash and cash equivalents</b>	<b>1,268</b>	<b>-9,713</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>13,222</b>	<b>21,187</b>
Change in cash and cash equivalents due to changes in exchange rates	-320	187
<b>Cash and cash equivalents at end of period</b>	<b>14,170</b>	<b>11,661</b>



# NOTES TO THE GROUP INTERIM REPORT

for the Period from January 1 to September 30, 2011  
of STRATEC Biomedical AG

## Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC AG as of December 31, 2010, were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of September 30, 2011, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2010 financial year. Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of September 30, 2011.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, Wirtschaftstreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC AG as of December 31, 2010 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€ thousand).

## Segment disclosures

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

There have been no changes in the segmentation of the Group's results compared with the consolidated financial statements as of December 31, 2010.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousands	Germany	EU	Other	Total
January - September 2011	14,547	44,197	21,411	80,155
	18.2%	55.1%	26.7%	100.0%
in € thousands	Germany	EU	Other	Total
January - September 2010	12,776	43,076	13,297	69,149
	18.5%	62.3%	19.2%	100.0%

### Research and development expenses

The expenses relating to research and project management, and to development services not fulfilling the capitalization criteria set out in IAS 38, amounted to € 4.3 million in the first nine months of the 2011 financial year (previous year: € 4.7 million). These have been reported, mainly as personnel expenses, in the company's consolidated statement of comprehensive income. Moreover, procurement volumes of around € 0.7 million (previous year: € 0.8 million) were incurred during the period under report in connection with materials used in research and development. These have been included in the cost of materials item.

### Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the statement of changes in group shareholders' equity on Pages 13 and 14.

The number of ordinary shares with a nominal value of € 1.00 each issued by STRATEC AG as of September 30, 2011, amounts to 11,671,795. These are all bearer shares.

### Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

As a one-off bonus payment, employees at STRATEC Biomedical AG received a total of 6,425 STRATEC shares from the company's holdings of treasury stock in February and April 2011. Furthermore, a total of 9,457 treasury stock were issued to employees in March 2011 to service stock options exercised by the respective employees within the employee stock option program.

STRATEC AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of € 12,223.00 of the company's share capital and to a 0.11 % share of its equity.

### Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

	<b>Board of Management / Managing Directors</b>	<b>Employees</b>	<b>Total</b>
Outstanding on 12.31.2010	154,500	50,964	205,464
Issued	45,000	2,800	47,800
Exercised	97,500	6,684	104,184
Lapsed	0	1,280	1,280
Outstanding on 09.30.2011	102,000	45,800	147,800

A total of 1,800 and 45,000 stock option rights were granted to company employees and to members of the Board of Management respectively on the basis of option agreements dated February 1, 2011, March 21, 2011 and September 28, 2011.

Members of the Board of Management and employees exercised 97,500 and 6,684 stock option rights respectively in the first nine months of 2011. A total of 9,457 treasury stock shares were issued and 102,769 shares created from conditional capital to service these stock option rights.

Furthermore, 1,280 stock option rights lapsed during the period under report.

### Employees

Including temporary employees the STRATEC Group had a total workforce of 484 employees as of September 30, 2011 (previous year: 440).

### Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

### Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group for the remaining months of the financial year.

## ADDITIONAL INFORMATION

### FINANCIAL CALENDAR

**October 26, 2011**                      Interim Report as of September 30, 2011

Furthermore, based on current planning, STRATEC will also be taking part in the following capital market conferences in 2011:

**November 2011**      WestLB Deutschland Conference, Frankfurt am Main, Germany  
                                 Berenberg Bank European Conference, London, UK

Partially incomplete / subject to amendment

## ABOUT STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE 0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

Further information about STRATEC is available on the internet at [www.stratec.com](http://www.stratec.com).

## IMPRINT

### Published by

STRATEC Biomedical AG  
Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0  
Fax: +49 7082 7916-999  
[info@stratec.com](mailto:info@stratec.com)  
[www.stratec.com](http://www.stratec.com)

### Investor Relations

ANDREAS KÜNZEL  
Phone: +49 7082 7916-185  
Fax: +49 7082 7916-999  
[a.kuenzel@stratec.com](mailto:a.kuenzel@stratec.com)

ANDRE LOY  
Phone: +49 7082 7916-190  
Fax: +49 7082 7916-999  
[a.loy@stratec.com](mailto:a.loy@stratec.com)

## NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures from an economic point of view that are required by the relevant international financial reporting standards (IFRS). These disclosure should be regarded as a supplement, rather than as a substitute for the notes to be disclosed under IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

**STRATEC BIOMEDICAL AG**

Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

[info@stratec.com](mailto:info@stratec.com)

[www.stratec.com](http://www.stratec.com)